2026 年 2 月 – 第 24 页

Finance

长安启动2026全球测试季，同步发布SDA智能更新与钠离子电池战略

February 5, 2026

(SeaPRwire) - 中国牙克石，2026年2月5日——Changan Automobile在内蒙古牙克石举办了一场主题为“Changan SDA智能升级暨全球钠离子电池战略发布”的发布会。活动期间，Changan正式发布了其全球钠离子电池战略，并宣布2026年全球测试季正式启动。 Changan正在加速钠离子电池技术的进步，作为其全球电池战略的一部分。China Changan Automobile Group首席品牌官谭本宏指出，Changan将在不久的将来继续在多个品牌下推出搭载钠离子电池的新车型。谭本宏先生表示：“从极限条件到日常驾驶——Changan对极限的每一次追求，最终都是为了保护我们每一位用户的日常出行。” 在极低温条件下，钠离子电池系统展现出稳定的放电能力，验证范围超过零下40摄氏度。为验证固有安全性，Changan和CATL进行了超越国家标准的极端滥用测试，包括满电状态下的挤压、针刺、钻孔和完全切割，所有测试均未发生火灾、爆炸、冒烟或热失控。 SDA Intelligence：极限条件下的验证此次发布会还展示了SDA Intelligence，它将安全从被动防护提升到主动的、AI驱动的车辆稳定。在牙克石进行的极寒实况测试中，来自AVATR和Changan品牌的车辆——包括CS系列、CHANGAN DEEPAL和CHANGAN NEVO——在严酷的低温条件下接受了真实场景的考验。 AVATR 12在80公里/小时的速度下，轮胎爆胎后完成了冰面紧急变道。CHANGAN NEVO Q05在自适应巡航控制（ACC）挑战中识别出低摩擦冰面上的障碍物，并实现了受控紧急停车。CHANGAN DEEPAL L06在雪地高速环形漂移挑战中展示了快速姿态调整能力。 Changan以用户为中心的安全理念建立在“验证先行”的方法之上，并由强大的验证体系和全球先进的实验室基础设施提供支持，包括Western Automotive Proving Ground和CHANGAN SDA Lab，从而实现贯穿整个车辆生命周期的全面、全场景验证。牙克石只是起点。2026年全球测试季将包括东南亚的高湿耐久性测试和欧洲阿尔卑斯山的高海拔底盘调校。在欧亚大陆，Changan将以AVATR 12为测试车辆，进行以冰雪信心为中心的冬季测试。在拉丁美洲，Changan将进行从坎昆到梅里达的墨西哥越野驾驶，重点关注长距离可靠性。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 CONTACT: Xu Ruiyue xury1@changan.com.cn

CHC Navigation 在 CHCNAV Connect – 2026 全球合作伙伴大会上强调强劲的国际增长和技术驱动战略

February 5, 2026

(SeaPRwire) - 上海，2026年2月5日 -- CHC Navigation在2026年国际经销商大会上展示了其增长前景和技术路线图，此次大会汇聚了来自全球地理空间市场的合作伙伴。在主题演讲中，首席执行官George Zhao强调，CHC Navigation正通过持续投资核心技术、集成工作流程以及与国际合作伙伴网络加强本地执行，朝着全球地理空间技术领导者的目标迈进。他指出，地理空间行业已进入一个新阶段，用户对精度、一致的数据质量、无缝的工作流程和可预测的总拥有成本的期望越来越高。 Zhao强调了公司强劲而均衡的增长态势，这得益于多元化的产品组合和加速的国际发展势头。2025年，CHC Navigation报告国际收入显著增长，同时在EMEA、亚洲和美洲地区持续扩张。他表示，国际业务是公司核心的增长引擎，并得到了持续的客户亲近度投资的支持。演讲的一个核心主题是技术自主和集成。Zhao解释说，控制从定位引擎和传感器到算法、硬件平台和云服务的价值链，能够实现更快的创新周期。这种方法支持CHC Navigation在测量、3D现实捕捉、机器控制、海洋测量、监测和定位服务等领域提供实用解决方案的能力。演讲还讨论了现实捕捉技术向日常运营的快速转变。据Zhao介绍，手持扫描仪、移动测绘、混合测量和无人平台正日益成为建筑工地、基础设施项目和资产管理工作流程中的常规工具。CHC Navigation正专注于技术集成和可访问性，以帮助用户在实际环境中更有效地部署这些工作流程。 Zhao指出，人工智能正被纳入其中，以提高工作流程效率，包括现场精度支持以及对点云和交付成果更自动化的数据处理。他补充说，CHC Navigation将继续将这些功能集成到产品系列中，以改善用户体验和运营效率。在演讲结束时，Zhao重申了CHC Navigation通过区域办事处、认证服务中心和应用专家支持的全球化布局和本地化执行的承诺。他表示，公司2026年的发展方向建立在技术领导力、市场扩张以及与经销商网络的合作之上。 “通过掌握核心技术，提供集成解决方案，并与我们的合作伙伴进行本地化执行，我们正在共同进步，构建一个互联互通的地理空间未来，”Zhao说。联系信息：Xu Can CHC Navigation本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

“心灵专区”到“海龟三明治”：米兰奥运村探秘

February 5, 2026

(SeaPRwire) - 对于在米兰奥林匹克村居住的1559名居民来说，有个明智的建议：不妨走进园区的Zona Mentale，也就是“心灵区”。这个空间对所有将村庄视为家园的运动员、教练和团队成员开放，旨在帮助他们放松。你可以给亲朋好友写明信片：用纸张，而不是屏幕。你可以像任何幼儿园小朋友一样涂色，让自己从眼前这项重大任务中解脱出来：在全球最大的体育盛事中参赛。你一生都在为这一刻做准备，而是否能再有这样的机会，可能要等四年了。请递给我红色蜡笔。心灵区的后面有一个小区域叫做“交流舱”，运动员们可以在这里倾心交谈或向心理健康专家倾诉。还有一张沙发，用小屏障隔开以保证隐私；运动员可以用它小睡一会儿，或者戴着耳机听音乐。 “有一位运动员每天都会来这里读几个小时的书，”格洛丽亚·维塞拉斯说，她是一名工作人员——也是1980年莫斯科奥运会的参与者——负责管理这个空间。她说这位书虫来自意大利。不妨赌她为东道主国家争光。这个村庄分布在一个前铁路场地上的六栋住宅楼里，比其他版本的村庄小：其一，冬奥会的运动员人数比夏季奥运会少；其二，比赛分散在意大利北部，每个村庄的人数较少。还有位于科尔蒂纳丹佩佐的村庄，那里是女子高山滑雪、以及……和……的举办地；安特塞尔瓦的安托尔斯-安特塞尔瓦，这里正在举办冬季两项比赛；普雷达佐（北欧两项和跳台滑雪）；博尔米奥（男子高山滑雪和……）；以及利维尼奥（自由式滑雪、单板滑雪）。在所有村庄中，床铺比最近几届奥运会的更……。在米兰，比赛结束后这里的空间将改为学生宿舍——加拿大团队在其住宅区前竖起了一只驼鹿——娱乐区有一张桌上足球桌，周二下午两名法国女子冰球运动员正在那里一决高下；一张曲棍球桌；还有一个电子游戏区。奥运选手可以玩……赛车游戏，或者假装在网球比赛中当……。排行榜显示最佳奥运电子游戏玩家：如果他们在冰上也表现不佳，这或许是一点小小的安慰。米兰村庄的食堂——午餐时，德国和芬兰的奥运选手成群坐在一起，但各自属于自己的小圈子，就像大一新生和大二的潮人一样——每天供应3000个鸡蛋和近1000磅意大利面。周二午餐的菜单包括 cous cous、三文鱼、箭鱼和玛格丽特披萨，当然还有其他菜品。在巴黎奥运会上，……成为了黑马明星。米兰会有类似的网红美食吗？比如本周推出的海龟三明治：它宣传是小麦粉、盐、啤酒酵母、特级初榨橄榄油和葵花籽油的混合物？嗯。我可不觉得它能登上领奖台。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

ACN Newswire

Banle Group Hosts Inaugural ESG Forum with Industry Leaders, Pioneering Green Shipping Solutions Amid Global Decarbonization Push

February 5, 2026

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Banle Group (“Banle” or the “Group”), a leading Asia-Pacific marine fuel logistics provider, hosted its landmark inaugural ESG Forum — "Charting the New Horizon: Powering Green Shipping with Sustainable Fuels" — uniting top maritime executives, financiers, legal experts, and climate scientists to address the shipping industry's urgent decarbonization challenges on February 2.Speaker Lineup Tackles Critical IssuesThe forum featured exclusive insights from:Dr. Teck Lim Chia, Chairman and CEO of Banle GroupMs. Karen Cheah Yee-Lynn, Independent Director of Banle Group, Partner of Chooi & Company, Immediate Past President of the Malaysian Bar and EXCO Member of LAWASIAMr.Matt Liu Ming-Hsuan, SVP Capital Solutions, Cathay United BankDr.Wilson Cheung Wai-yin, Polar Explorer, Glaciologist and Policy Advisor, Polar Research and Expedition ConsultancyMs.Rebecca Zhang, Senior Manager Sustainable Finance, Commercial Banking, Hong Kong, HSBCThe forum served as a dynamic platform for thought leadership and dialogue, featuring a series of presentations addressing critical topics such as the impact of climate change on global shipping, evolving sustainability-related regulations, and innovative green and sustainability-linked financing solutions.Dr.Teck Lim Chia addressed in the keynote speech, “The global shipping industry stands at a pivotal moment. Rapid regulatory changes, geopolitical tensions, climate challenges, and technological advancements are reshaping the landscape at unprecedented speed. Yet, we are dedicated to fostering a collaborative environment where stakeholders can come together to share insights and develop strategies for a more sustainable future.”On the forum, Ms.Karen Cheah talked about how ESG has become a legal, economic, and moral imperative to safeguard planetary health – and how governments, businesses, courts, and capital markets at an international level must work together holistically to turn sustainability from aspiration into measurable action. She said, “We must establish planetary health metrics to track environmental, health, and risk impacts on all of us. This requires not only a measurement to gauge our progress but also a strategic plan to communicate these metrics, drive global awareness, and educate society at large. Moreover, we must integrate these metrics into governance structures at organizational, domestic, national, and international levels. We must engage in responsible business practices aligned with ESG components and ensure a robust framework for planetary health is implemented globally. Once we align collectively, we can systemize this framework for lasting impact.”Mr.Matt Liu shared his insight on integrating ESG features into financing strategies, “Green loans excel when companies have a clear, specific investment plan. Sustainability-Linked Loans (SLLs) operate under a distinct logic: their Key Performance Indicators (KPIs) must reflect material sustainability issues, be measurable, traceable, and independently verifiable. Crucially, Sustainability Performance Targets (SPTs) must balance ambition with feasibility, remaining achievable within the company’s operational capacity. Unlike green loans, SLLs do not restrict proceeds to green activities; instead, they demonstrate sustainability commitment through performance-linked financial mechanisms. Beyond loans and bonds, nearly all liability-style financial products can now integrate green or sustainability elements. This flexibility allows companies to align financing with sustainability goals while maintaining operational practicality, driving both environmental progress and financial innovation.”Dr.Wilson Cheung addressed his dedication to geoscientific education and advocacy, and talked about the responsible opportunities for the shipping industry, “Responsible opportunities in the shipping industry begin with recognising that the Arctic is not only a shortcut, but also a living homeland and a fragile climate regulator for the planet. New polar sea routes can reduce transit time and fuel use, yet they cross waters where infrastructure is scarce, ecosystems are vulnerable, and Indigenous communities depend on sea ice for culture and survival. True leadership means investing in cleaner fuels, ice-class vessels, and robust search-and-rescue capacity, while strictly limiting black carbon emissions and respecting international polar regulations. It also means listening to local knowledge that has guided safe travel on ice for thousands of years and integrating that wisdom with modern science and satellite data. If the industry embeds ESG principles into every Arctic voyage, these emerging routes can become a model of responsible innovation rather than a new frontier of unchecked risk.”Ms.Rebecca Zhang shared recent shipping industry transition trends from a sustainable finance perspective: “Regulations are constantly evolving, and so must global efforts to tackle climate change and make maritime transport more sustainable. Innovative solutions are emerging, and shipowners are exploring alternative energy options such as biofuels, bio-LNG, and bio-gas. The development of clean technologies is accelerating the industry’s systemic shift towards sustainability.”The forum concluded with a lively and interactive networking among participants, who exchanged ideas and reaffirmed their collective commitment to advancing sustainable practices throughout the shipping industry.Banle Group's sustainability leadership by example through its operational practices was prominently showcased, highlighting its ongoing efforts to spearhead industry decarbonization and responsible practices. Through initiatives like its participation in the EcoVadis rating system and advocacy for diverse sustainable marine fuels, Banle continues to drive meaningful transformation across the shipping sector.Looking ahead, the Banle Group remains committed to hosting future forums that foster dialogue, innovation, and collaboration for a more sustainable maritime ecosystem.Dr.Teck Lim Chia added: "This is just the beginning. Banle will continue driving practical decarbonization solutions for our industry and clients."For more information about Banle Group and its sustainability initiatives, please visit www.banle-intl.com.Photo Caption 1: Dr. Teck Lim Chia (centre) presented souvenirs to all speakers and panelists as a token of appreciation.Photo Caption 2: Panelists engaged in a discussion on the theme: “Charting the New Horizon: Powering Green Shipping with Sustainable Fuels”. Ms. Karen Cheah (left) served as moderator, guiding the discussion while also contributing her insights as a panelist.Photo caption 3: Attendees gathered at the ESG Forum, showcasing a shared commitment to sustainable practices and innovative solutions in the shipping industry.About Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications, as well as EcoVadis Silver Medal.For more information, please visit: https://www.banle-intl.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

万利集团与行业领袖举办首届ESG论坛在全球减碳浪潮下开创绿色航运解决方案

February 5, 2026

香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 亚太地区燃油供应服务商万利集团（以下简称（「万利」或（「集团」）于2月2日举办以「开拓新视野：以可持续燃料推动绿色航运」为主题的首届环境、社会与治理（ESG）论坛。论坛汇聚航运高管、金融家、法律专家及冰川学家，共同探讨应对航运业迫切减碳挑战的方案。以下演讲嘉宾阵容于论坛探讨关键议题，分享独特见解：万利集团主席兼行政总裁谢威廉博士万利集团独立董事、Chooi & Company合伙人、马来西亚大律师公会前会长及LAWASIA执行委员会委员谢依玲女士国泰世华银行资本市场暨顾问部协理刘名轩先生极地探险家、冰川学家及政策顾问、Polar Research and Expedition Consultancy创办人／冰川学家与远征总监张伟贤博士汇丰香港工商金融可持续金融高级经理张雯瑾女士是次论坛为思想领袖提供了一个互动及对话的平台，并透过演讲嘉宾的专题讲座探讨若干关键议题，包括气候变化对全球航运的影响、持续转变的可持续发展相关法规，及创新绿色及可持续发展挂钩融资解决方案。谢威廉博士在主题演讲中表示：「全球航运业正处于关键时刻，迅速转变的监管法规、紧张的地缘政治局势、气候挑战及技术发展正以前所未有的速度重塑行业格局。因此，我们期望打造一个协作环境，让持份者聚首一堂，分享见解并制定策略，以构建可持续未来。」在论坛上，谢依玲女士讨论ESG如何成为保障地球健康的法律、经济和道德必要条件，并强调政府、企业、法院及资本市场必须在全球层面上通力合作，将可持续发展愿景转化为可量化的实际行动。谢女士表示：「我们必须建立全球健康指标体系，以系统追踪环境影响、健康影响及风险对全人类的综合作用。这不仅需要量化工具评估进展，更需制定战略传播方案以提升全球认知、推动全民教育。同时，必须将指标体系深度融入组织、国家及国际治理架构，在本土和全球层面同步实施。企业应践行负责任的商业伦理，全面对标ESG准则，构建普适性的全球健康框架。唯有通过全球协同标准化，方能实现框架的系统化落地与长效运行。」刘名轩先生分享其对将ESG特征融入融资策略的见解：「绿色贷款（Green Loans）在企业拥有明确、具体的投资计划时尤其适合。可持续发展挂钩贷款（Sustainability-Linked Loans，SLLs）遵循独特的逻辑：其关键绩效指标（KPIs）必须反映重大的可持续议题，并且可量化、追踪和独立验证。最重要的是，可持续性绩效目标（Sustainability Performance Targets，SPTs）必须在『积极进取』和『实际可行』之间取得平衡，确保在公司的运营能力范围内有机会实现目标。与绿色贷款不同，SLLs不限制所得款项只用于绿色活动上；相反，SLLs通过与绩效挂钩的金融机制展示可持续承诺。除了贷款和债券，几乎所有负债型金融产品现在都可以加入绿色或可持续性元素。这种灵活性使得企业能够将融资与可持续目标结合在一起，一方面保持运营的实际可行性，也能推动环境进步与金融创新。」张伟贤博士分享其对地球科学教育与倡导的坚定承诺，并探讨航运业的负责任发展机遇：「航运行业的可持续发展机遇始于认识到北极不仅是一条捷径，更是一个生机勃勃的家园和地球脆弱的气候调节器。新开通的极地航线虽能缩短运输时间、降低燃油消耗，但其航经水域存在基础设施匮乏、生态系统脆弱、原住民依赖海冰维系文化与生存等挑战。真正的领导力意味着要投资于更清洁的燃料、冰级船舶和强化搜救能力，同时严格限制黑碳排放（Black Carbon Reduction），并尊重国际极地法规。这也意味着倾听在冰上安全旅行了数千年的地方知识，并将这种智慧与现代科学和卫星数据融合。如果行业将ESG原则嵌入到每一次北极航行中，这些新兴航线能够成为可持续创新的典范，而非不受控制风险的新边界。」张雯瑾女士从可持续金融角度分享航运业转型趋势：「监管不断变化，应对气候目标和实现可持续海洋运输的策略亦需要与时并进。目前，创新方案也应运而生，船东群体正探索生物燃料、生物液化天然气（bio-LNG）、生物沼气等替代能源方案。清洁技术研发持续，有助推动全球航运业向可持续模式的系统性转型。」论坛在与会人士热烈交流中圆满结束，除交流意见外，他们亦重申对推动航运业可持续发展的共同承诺。万利集团在可持续发展领域的领导地位突出，显示其在引领行业减碳与推行负责任实践方面的不懈努力。集团亦透过参与EcoVadis永续性评级系统及支持多元化可持续船用燃料，持续推进航运业的有效转型。展望未来，集团将继续举办更多论坛，促进对话交流、创新及合作，从而建立更可持续的海洋生态系统。谢威廉博士补充：「以上不过是个开端，万利将继续为行业及客户制定切实可行的减碳解决方案。」有关万利集团及其可持续发展方案的更多讯息，请浏览 www.banle-intl.com。图片说明1：谢威廉博士（中）向演讲嘉宾及论坛成员致送纪念品以示感谢。图片说明2：论坛成员就「开拓新视野：以可持续燃料推动绿色航运」主题进行讨论。谢依玲女士（左）担任主持人，引领讨论并以论坛成员身份分享见解。图片说明3 ：与会人士在 ESG 论坛上聚集，展现了对航运业可持续实践和创新解决方案的共同承诺。关于万利集团万利集团成立于 2015 年，以CBL International Limited（纳斯达克：BANL）在纳斯达克股票市场上市。我们致力于为客户提供一站式燃油供应服务，被业内称为燃油供应服务商。我们主要通过当地实体供货商为船舶提供燃油加注服务，遍布比利时、中国、香港、印度、日本、韩国、马来西亚、毛里裘斯、巴拿马、菲律宾、新加坡、台湾、泰国、土耳其和越南，共覆盖65个港口。集团积极推动可持续燃料，并已取得ISCC EU和ISCC Plus认证，以及EcoVadis银奖。如欲了解更多信息，请到集团网站 https://www.banle-intl.com 浏览。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SLEEK EV 获得由 KYMCO Capital 领投的A轮首轮850万美元融资，早期参与方包括 January Capital、Krungsri Finnovate 和 ORZON Ventures

February 5, 2026

(SeaPRwire) - 曼谷，2026年2月5日 -- SLEEK EV（以下简称“SLEEK”或“公司”），一家在车辆电气化领域，主要以电动摩托车为主的领先技术制造商和创新者，今天宣布其A轮融资首期已完成850万美元。本轮融资由KYMCO Capital领投，KYMCO Capital是由全球动力运动制造商Kwang Yang Motor Co., Ltd (KYMCO)以及来自台湾和中国大陆的二十多家供应链企业共同投资的私募股权基金。这项投资标志着公司在准备加速SLEEK在泰国全境扩张并定位泰国为东南亚电动摩托车枢纽方面的一个重要里程碑。这笔资金将使SLEEK能够扩大东部经济走廊（EEC）沿线扩建工厂的生产能力，加速产品研发以提供尖端的人工智能驱动软件和人工智能代理，从而增强用户体验，并通过增加七倍以上的EV S-Charge充电站来深化其在泰国的地理足迹。利用与PTT OR、Krungsri Auto、Toyota Tsusho和Grab等现有合作伙伴的关系，SLEEK将继续与经销商和国家监管机构建立新的战略渠道伙伴关系，以提高市场份额和产品交付，并为电动摩托车的区域充电和电池更换设定新标准，分别实现安全性、质量和运营效率。 SLEEK EV的长期目标是成为亚太地区值得信赖的全栈电动摩托车操作系统，在这个系统中，合作伙伴协同合作，数据复合增长，行动转化为一种新的城市出行方式。KYMCO Capital作为战略合作伙伴和投资者，将为SLEEK EV带来60年两轮车行业的经验，并将支持其优化供应链、协同电池和充电/换电技术的普及，并加速其在东南亚的销售分销。 SLEEK EV首席执行官兼联合创始人Kantinun Tunveenukoon (Ben)表示：“KYMCO Capital的这项投资具有战略意义。它验证了我们的技术以及在全球市场竞争的能力。SLEEK EV不仅仅是一家电动摩托车制造商。我们正在通过端到端的生态系统解决方案重新定义车辆电气化——从制造、充电基础设施，到将一切连接在一起的集成软件。我们的目标很简单。我们希望将泰国打造成东盟的电动摩托车枢纽。我们的目标是到2026年底成为泰国排名第一的电动摩托车品牌。”他补充道：“与KYMCO Capital合作，我们正在电动汽车生态系统上加倍投入，提供优质产品、强大的技术堆栈以及志同道合的利益相关者，他们可以与我们一起推动这一进程。” KYMCO Capital管理合伙人Gary Ting分享道：“KYMCO Capital致力于支持泰国电动汽车生态系统，这基于他们在台湾和中国大陆所建立的基础。对SLEEK EV的这项投资体现了我们在东南亚市场的生态系统。这种伙伴关系体现了通过车辆电气化实现下一代城市基础设施转型。凭借KYMCO深厚的能力与SLEEK EV的产品相结合，我们看到自己正在赋能所有企业和政府实现电动化。我们坚信SLEEK EV在泰国的生态系统方法将在建设更绿色的未来中发挥至关重要的作用。” 关于SLEEK EVSLEEK EV总部位于新加坡并在泰国运营，是一家物联网（“IoT”）赋能的电动摩托车制造商，专为城市骑行设计。SLEEK的使命是重新定义城市生活的车辆电气化，实现可持续的未来。SLEEK的技术堆栈全面，包括配备物联网的摩托车硬件，并与移动应用程序同步，为用户提供无缝的客户体验。欲了解更多关于SLEEK EV的信息，请访问：关于KYMCO CAPITALKYMCO Capital是一家专业的基金管理公司，专注于全球出行领域。目前管理着总资产管理规模（AUM）超过1000亿新台币的股权投资基金，KYMCO Capital的投资组合涵盖电动汽车（EVs）、车联网（IoV）、人工智能（AI）、电池和能源管理等核心技术。我们的战略足迹遍及台湾、美国、中国大陆、东南亚和日本。为响应全球“净零”转型，KYMCO Capital利用“资本运营与业务发展”战略，构建跨行业、跨国整合平台。欲了解更多关于KYMCO Capital的信息，请访问：投资者和媒体垂询，请联系:SLEEK EV PTE. LTD.电子邮件: KYMCO CAPITAL电子邮件: 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。联系方式：投资者和媒体垂询，请联系: SLEEK EV PTE. LTD. 电子邮件: press@sleekev.com KYMCO CAPITAL 电子邮件: info@kymcocapital.com

卓正医疗上市在即：认购火爆以独特商业模式撬动业绩逆势增长

February 4, 2026

香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 随著居民健康消费意识持续提高和消费升级，中国私立医疗服务市场，特别是私立中高端医疗服务机构迎来发展窗口。其中，卓正医疗控股有限公司（"卓正医疗"，股份代号：2677.HK）以独特的家庭医疗模式为核心，融合全科室服务覆盖与线上线下一体化体验，深耕中高端市场多年，已成长为行业领先企业之一。2月3日，卓正医疗结束港股招股，发售价定为66.60港元，预计于2月6日正式登陆港交所。招股期间，公司市场认购热情持续高涨，据富途公开数据显示，其孖展认购额高达665.29亿港元，约超购2103.31倍，成为近期港股市场中备受追捧、认购火爆的新股，机构与个人投资者踊跃布局，用实际行动彰显对公司商业模式、行业地位及未来增长前景的坚定信心。从"个人诊疗"到"家庭入口"：平台化生态铸就增长基石在中高端健康服务赛道竞争日趋激烈的当下，卓正医疗跳出传统医疗机构的发展模式，以家庭为核心深耕高价值会员体系，打造独树一帜的"超级用户"生态，实现复购率与忠诚度双双领跑行业，构筑起坚实的品牌与市场壁垒。不同于传统医疗机构单人单次的低频消费模式，卓正医疗通过整合儿科、齿科、眼科、皮肤科、内科及妇科等超过六大核心专科，为同一家庭的不同成员提供一站式、跨生命周期的健康解决方案，让自身从一个解决特定健康问题的"站点"，转变为一个家庭健康管理的"总入口"和决策中心。当单一家庭成员获得信任并建立服务关系后，带动其他家庭成员自然导入，实现了客户基础的有机扩张和消费场景的极大延伸。这种平台化生态显著提升了客户生命周期价值，推动公司收入持续增长。在"家庭入口"的平台上，卓正医疗进一步通过"卓正会员计划"深化用户关系，将平台流量高效转化为长期、高粘性的"超级用户"。该计划为家庭提供优先预约、专属套餐等权益，不仅提升了服务体验，更在心理层面建立了"健康管家"式的信任纽带，持续提升用户粘性。截至2025年8月31日，公司已拥有超过11.6万个会员帐户，会员续费率达67%，而整体患者回头率高达82.7%，印证了其服务模式强大的客户锁定能力。财务表现逆势增长数字化 AI 化重塑服务新范式凭借独特的商业模式与高效的运营管理，卓正医疗在医疗服务行业部分机构面临盈利压力的背景下，实现了收入与利润的双重逆势增长。数据显示，2022年至2024 年，卓正医疗营收从4.7亿元增长至9.6亿元，复合年增长率达42.3%，营收规模实现翻倍增长；毛利从4398万元跃升至2.3亿元，复合年增长率高达126.7%，盈利能力大幅提升；2024年，公司更是成功扭亏为盈，经调整净利润1,070万元，实现了从规模增长到盈利增长的质的飞跃。尤为难得的是，卓正医疗的业绩增长并非依赖医保加持或高额营销投入，其营销费用占收比常年维持在2%上下，真正依靠口碑获客实现可持续增长，这种健康的盈利模式也成为资本市场看好公司的重要原因。而数字化与AI技术的深度应用，则为卓正医疗提升运营效率、打造高粘性健康服务生态提供进一步助力。公司自主搭建了HMS医院管理系统、DMS卓正管理系统、卓正数据中台等数字化平台，实现集中化、标准化及数字化的管理，不仅大幅提升医护人员的运营效率，更让用户享受到便捷、高效的诊疗体验，进一步提升了用户满意度。此次港股IPO，卓正医疗计划将把募资净额的35%用于医疗人工智能应用的人才培养、技术研发与外部合作，旨在通过AI技术赋能，革新医疗服务提供方式与运营效率。未来，随著AI技术与医疗服务的深度融合，卓正医疗有望进一步优化使用者体验，提升服务效率，让数字化、智能化成为公司持续增长的新引擎。从千亿健康消费赛道的稀缺标的，到认购火爆的港股IPO新星，卓正医疗的资本市场之路，是其多年深耕高价值健康服务、坚持质量与口碑的必然结果。凭借高复购高忠诚的超级用户生态，公司构筑了行业领先的商业模式壁垒；逆势增长的财务表现，印证了其盈利模式的可持续性；借助数字化与AI化的前瞻布局，公司有望打造了高粘性的健康服务新范式，为长期增长注入强劲动力。在资本赋能下，公司有望进一步夯实自身在中高端健康服务赛道的龙头地位，其上市后的表现，值得长期关注。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations

February 4, 2026

BRISBANE, AUS, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - Annature, Australia's leading eSignature and Identity verification provider, has announced the release of its 21 CFR Part 11 compliant electronic signature module, enabling organisations operating in FDA‑regulated environments to execute electronic records with confidence.The new capability ensures Annature customers can meet the U.S. Food and Drug Administration's requirements for electronic records and electronic signatures under 21 CFR Part 11, a regulation that governs data integrity, signer authentication, and auditability across industries such as life sciences, pharmaceuticals, biotechnology, and clinical research.The release has been driven by growing demand from U.S.-based and multinational organisations seeking a modern, compliant alternative to legacy eSignature platforms. Several customers operating in regulated environments have already transitioned to Annature as part of broader digital transformation initiatives, prompting the company to formally introduce Part 11 support as part of its international product roadmap."As we continue to grow globally, it's critical that Annature supports the regulatory frameworks our customers operate under," said Corey Cacic, CEO of Annature. "Our 21 CFR Part 11 module allows organisations subject to FDA requirements to use Annature with confidence, knowing their electronic signatures meet the necessary compliance standards."The module introduces controls aligned with Part 11 expectations, including secure signer authentication, tamper‑evident audit trails, and strong linkage between electronic signatures and the records they relate to. These features ensure electronic signatures executed through Annature can be relied upon in regulated workflows and during regulatory review.Kim Steel, Founder and Managing Director of SAPRO - a boutique CRO supporting niche biotech and pharmaceutical companies with commercially sponsored Phase I-III full-service clinical trials has welcomed the release."For organisations operating in regulated environments, compliance with 21 CFR Part 11 is not optional - it is fundamental," said Steel. "It is encouraging to see Annature, an Australian technology provider supporting international regulatory requirements that are critical to our industry and our clients. Solutions like this enable sponsors to operate confidently on a global stage, without reliance on outdated or overly complex legacy systems, while remaining inspection and audit-ready at all times."The launch further strengthens Annature's position as a global‑ready eSignature platform, supporting organisations that operate across jurisdictions with varying compliance obligations. The 21 CFR Part 11 module is available now and can be enabled for customers who require FDA‑compliant electronic signatures.About AnnatureAnnature is Australia's leading eSignature and Identity verification provider, trusted by over 6,700 businesses. With a Pay as you go model and deep integration across the business app ecosystem, Annature delivers secure, affordable, and locally supported solutions for professionals across the country. Annature's growing product suite also includes integrated payments and compliance features designed to support both domestic and international regulatory requirements.https://www.annature.com.auCONTACT:Name: Corey CacicEmail: corey@annature.com.auSOURCE: Annature Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States

February 4, 2026

MORTSEL, BE, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide.The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights.AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinical decision-making through connected, high-performing access to images and data.Best in KLAS® - Enterprise Imaging (United States)Enterprise Imaging for Radiology: ranked #1 with a 93.2% score in the PACS (Small - under 300k studies) segment.XERO® Viewer: ranked #1 with a 92.1% score in the Universal Viewer (Imaging) segment for the third consecutive yearEnterprise Imaging VNA: ranked #1 with a 89.8% score in the Vendor Neutral Archive (VNA) segment for the second consecutive year."Being recognized across three Enterprise Imaging segments - including multiple consecutive wins - is a powerful affirmation of our clinician-first strategy," said Nathalie McCaughley, President of AGFA HealthCare. "Healthcare organizations trust us to deliver imaging environments that truly support clinicians in their daily work, while enabling IT and clinical leaders to operate with confidence, performance, and long-term vision. This recognition reflects the strength of our partnerships and our unwavering focus on empowering care teams through connected, intelligent imaging."Commenting on the awards, Adam Gale, CEO of KLAS Research, said:"The Best in KLAS winners have earned the trust of their customers over the past year. With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come."Monique Rasband, Global Vice President of Imaging at KLAS Research, added:"AGFA HealthCare's strong performance across multiple Enterprise Imaging segments reflects consistent customer feedback. Organizations recognize the value of solutions that help imaging teams work efficiently today while providing a clear path for future growth and innovation."The Best in KLAS awards are based on direct feedback from healthcare providers and recognize vendors who consistently demonstrate excellence through partnership, performance, and responsiveness to customer needs.AGFA HealthCare will celebrate its Best in KLAS recognition during HIMSS 2026, alongside customers and partners, as part of its continued commitment to advancing connected, intelligent, and human-centered imaging at scale.KLAS referencesBest in KLAS Awards overview: 2026 Best in KLAS Awards: Software and Services ReportEnterprise Imaging segments reports: 2026 Best in KLAS Awards: Software and Services ReportAbout AGFA HealthCareAt AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That's why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one's thought process, and each clinician has everything they need to perform at the top of their craft. That's life in flow.This belief shapes everything we do - guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.comand follow us on LinkedIn.AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.About KLAS ResearchKLAS Research is a leading healthcare IT data and insights company dedicated to improving global healthcare delivery by amplifying the voice of healthcare providers. Celebrating its 30th anniversary in 2026, KLAS evaluates vendor performance through independent research based on direct customer feedback.Best in KLAS® is a registered trademark of KLAS Research.Press Contact: Jessica Baldry, Global Marketing & Communications Manager, AGFA HealthCare +44 1206 413052 jessica.baldry@agfa.comSOURCE: Agfa HealthCare Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing

February 4, 2026

HONG KONG, Feb 4, 2026 - (ACN Newswire via SeaPRwire.com) – NEW YORK, TAIPEI and TOKYO, Goldenstone Acquisition Limited (Ticker: GDST) (“Goldenstone”), a special purpose acquisition company listed in the U.S. capital market, today announced the execution of a letter of intent (LOI) for a proposed business combination with Deluxe Technology Group (“Deluxe”), a Taiwan-based leader in green technology machinery and sustainable material solutions. The merger is poised to capitalize on the rapidly growing sustainable packaging market, which is projected to reach over $250 billion by 2035.Amidst a complex global regulatory landscape and increasing consumer demand for eco-friendly products, Deluxe has distinguished itself by developing a proprietary and vertically integrated business model. The company’s patented pulp molding formula as well as technology, and use of agricultural waste as a raw material directly address the industry’s most pressing challenges: cost, performance, and scalability. This strategic approach has allowed Deluxe to achieve a significant breakthrough without geographical boundaries by offering compostable product lines that are not only environmentally superior but also cost-competitive with traditional plastics.“Deluxe Technology Group is not just participating in the green transition; they are leading it,” said the CEO of Goldenstone Acquisition Limited. “In a market where many companies struggle with the high cost and inconsistent supply of sustainable materials, Deluxe has created a scalable and economically viable solution. Their ability to turn agricultural waste into high-performance, cost-effective packaging is a game-changer for the industry. We are confident that this merger will unlock significant value for our investors and accelerate the global adoption of sustainable packaging.”The proposed merger is further strengthened by a strategic partnership with Oji Holdings Corporation (“Oji”), a Japanese pulp and paper manufacturing leader. This collaboration secures a stable supply of high-quality raw materials for Deluxe, mitigating a key risk that has hindered the growth of many other sustainable packaging companies. The partnership aligns with Oji’s commitment to contribute the “Harmony with Nature and Society” and will leverage Deluxe’s advanced technology to expand its global footprint.Deluxe’s forward-thinking strategy is also reflected in its recent expansion into the United States, establishing a physical presence to better serve its North American customer base, which includes several Fortune 500 companies. This move is particularly timely, as the North American compostable packaging market represented the largest share in 2025, at around 30% of the global market.“Our mission has always been to prove that sustainability and profitability can go hand in hand,” said Jason Lai, Founder and CEO of Deluxe Technology Group. “With over 130 patents and 20 global awards, our technology is a testament to this vision. By partnering with Goldenstone, we are gaining a strategic partner that will help us to navigate the public markets and to scale our solutions to meet the growing demand from the world’s largest brands. Together, we will accelerate the transition away from single-use plastics and create a more sustainable future.”Under the terms of the LOI, Goldenstone and Deluxe will work exclusively towards the negotiation and execution of a definitive merger agreement. The transaction is subject to due diligence, the execution of definitive agreements, and customary closing conditions, including regulatory and shareholder approvals. The proposed merger aims for a completion and subsequent public listing on the NASDAQ in 2026.Advisors and UnderwritersLoeb & Loeb LLP is serving as legal counsel to Goldenstone Acquisition Limited. MarcumAsia is serving as the Company’s auditor. Maxim Group LLC is acting as the financial advisor for the transaction. Chi Advisory Limited is serving as a financial advisor to Deluxe.About Goldenstone Acquisition Limited (Ticker: GDST)Goldenstone Acquisition Limited is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Goldenstone Acquisition Limited completed its US$57.5 million initial public offering on March 17, 2022, with about US$5.3M trust account balance as of September 30, 2025.About Oji Holdings Corporation (TYO: 3861)Oji is a leading Japanese company committed to resource sustainability and industrial innovation. Grounded in their philosophy to contribute to the "Creation of Innovative Value" and "Harmony with Nature and Society," Oji serves as both a strategic investor and a primary supplier of premium pure pulp to Deluxe, facilitating global expansion and environmental stewardship.About Deluxe Technology GroupHeadquartered in Taiwan with operations expanding into the US, Deluxe Technology Group is a premier provider of green technology machinery and sustainable product solutions. Specializing in pulp molding formula and ESG Technology, the company offers a complete turnkey solution. With over 20 global awards, and more than 130 patents, Deluxe provides compostable alternatives to plastic that are produced with industry-leading energy efficiency, with select products offering superior cost-competitiveness to plastic. Deluxe is supported by a prestigious consortium of institutional investors, validating Deluxe’s potential to lead the global green transition. Key investors include GIC (Government of Singapore Investment Corporation), Sigma Global Fund, JAFCO Asia, Oji Holdings Corporation, SBI & Capital 22, Cathay Private Equity, and Delta Electronics.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This includes statements regarding the intent to enter into a definitive agreement and the timeline for a 2026 merger. These statements are based on various assumptions and the current expectations of the management of Goldenstone and Deluxe and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Goldenstone and Deluxe.No Offer or SolicitationThis press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction where such offer, solicitation, or sale would be unlawful under the securities laws of any such jurisdiction.Contact Information:Investor Relations: Goldenstone Acquisition Limited Email: eddie@windfallusa.comEmail: ir@chi-am.comMedia Contact: Deluxe Technology GroupEmail: media@deluxe-tech.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

SuperX Strengthens Japan Presence to Explore AI Data Center Projects with Local Partners

February 4, 2026

OSAKA, Japan, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – February 4, 2026, SuperX Industries Co., Ltd. ("SuperX"), a Japanese subsidiary of SuperX AI Technology Limited (“NASDAQ:SUPX”), today announced the signing of an Memorandum of Understanding ("MOU") on February 4, 2026 with Digital Dynamic Inc. ("DD"), eole Inc. ("eole"), and Woodman Inc. ("Woodman"). This MOU builds on the parties’ prior cooperation to establish a comprehensive framework for the co-development of large-scale AI Data Centers (AIDC) across Japan.Advancing the Mie Prefecture Pilot ProjectFollowing the first MOU signed on January 30, 2026 in Osaka, Japan, the Parties entered into the MOU to further deepen collaboration by establishing a joint task force to pilot an AIDC project in Mie Prefecture, Japan with an initial facility capacity up to 4MW, subject to feasibility assessments, site conditions, regulatory approvals, and the execution of definitive agreements. The pilot initiative is intended to serve as a starting point for assessing potential future expansion up to 300MW in total capacity.Addressing Japan’s AI Infrastructure BottleneckThe shift toward modular architecture directly addresses Japan’s growing demand for the expansion of domestic AI capacity on an accelerated timeline. Unlike traditional "brick-and-mortar" builds that can take years to complete, SuperX’s modular approach accelerates deployment by reducing construction timelines significantly. This new pilot project is designed to be purpose-built for next-generation, liquid-cooled GPUs—capabilities often lacking in legacy data centers.Scalable delivery and reliable operationsPursuant to the MOU, the Parties intend to collaborate on the system-level integration of critical infrastructure, including advanced power systems and liquid cooling solutions essential for continuous AI workloads. The framework also contemplates the future integration of renewable energy components, such as solar and wind power, energy storage systems, and grid interconnection, subject to site conditions, commercial viability and regulatory approvals.To facilitate execution, a joint task force is expected to be established to define technical architecture, governance, and near-term milestones. SuperX will lead the provision of the modular system architecture and power system integration.Executive quote“Speed-to-market is the new currency in the AI race,” said Aiko Furukawa, the CEO of SuperX Industries Co. Limited. “This pilot project in Mie Prefecture is intended to demonstrate how we can deploy AI infrastructure with speed. Alongside our partners, we aim to demonstrate that modular scalability is the most viable path to meeting Japan's surging demand for AI.”Looking aheadLooking forward, the Parties intend to use the initial pilot as a reference framework to evaluate broader modular AIDC opportunities across Japan, including scalable pathways for expansion—subject to further feasibility assessments, regulatory approvals, site conditions, and the negotiation and execution of definitive agreements.About Digital Dynamic IncDigital Dynamic Inc. is one of Japan’s fastest-growing AI infrastructure operators, with a rapidly expanding deployment of NVIDIA-based inference GPU resources. In 2026, the company plans to complete AI data centers in Kagoshima Prefecture and Fukushima Prefecture, reinforcing Japan’s next-generation AI computing foundation.About eole Inceole Inc. is a publicly listed company in Japan with a rapidly growing presence in the domestic GPU server market. The company provides investment and business development support for AI data center development projects, playing an active role in advancing Japan’s AI infrastructure ecosystem.About Woodman IncWOODMAN Inc. is a Japanese technology company focusing on eliminating societal waste by transforming underutilized resources, such as surplus electricity and computing power, into new value. They specialize in constructing optimized computing environments for AI and HPC (High-Performance Computing), bridging the gap between energy infrastructure and, previously, blockchain/mining hardware.About SuperX AI Technology Limited (NASDAQ:SUPX)SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sgSafe Harbor Statement This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

JCN Newswire

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

February 4, 2026

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

ACN Newswire

云顶新耀宣布与麦科奥特达成MT1013独家商业化许可协议

February 4, 2026

上海, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK，以下简称"公司"），一家专注于创新药研发、临床开发、制造及商业化的生物制药公司，今日宣布与陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）签署独家商业化许可协议，获得MT1013在中国及亚太区（日本除外）的独家商业化授权。MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体(CaSR)及成骨生长肽(OGP)受体，开发主要用于治疗继发性甲状旁腺功能亢进症(SHPT)。此次战略合作将与云顶新耀现有肾科管线形成协同效应，强化产品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广泛的慢性肾脏病领域。根据协议，云顶新耀将向麦科奥特支付人民币2亿元首付款，以及最高不超过人民币10.40亿元的潜在监管及商业里程碑付款。中国III期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。MT1013是由麦科奥特自主研发的全球首创双靶点多肽新药，2025年获美国肾脏病学会（ASN）年会"Late-Breaking"收录。其开创性地融合了"钙敏感受体（CaSR）+成骨生长肽（OGP）模拟"双重作用机制，解决了PTH、钙、磷代谢平衡的问题，这一全新设计使其在治疗继发性甲状旁腺功能亢进（SHPT）及相关骨代谢疾病时，首次创造性的从源头上控制病情，且能通过直接激活成骨通路，主动促进骨形成与修复，实现从"间接抑制骨吸收"到"主动促进骨生成"的治疗创新升级。临床研究证实，MT1013在慢性肾病接受维持性血液透析伴继发性甲状旁腺功能亢进患者中，起效迅速、效力强且持久，安全性良好，在综合达标率（iPTH, 血钙，血磷均达标）、血钙钙化指标的控制及心血管获益前景上均展示出超越现有疗法的潜力。目前，MT1013正在中国开展针对该患者群体的III期临床研究，已入组超50%。SHPT是慢性肾脏病（CKD）患者最常见的严重并发症之一。该疾病导致钙磷代谢紊乱、甲状旁腺激素升高、骨病变、血管钙化等一系列病理变化，显著增加骨折、心血管事件和死亡风险，是影响CKD患者预后的关键因素。随着全球慢性肾脏病患者规模持续扩大，SHPT及其相关治疗需求亦不断增长。数据显示，全球CKD患者人数已由2019年的9.052亿人增至2024年的10.655亿人，预计2030年将超12亿人，2035年将超15亿人；同期全球SHPT患者人数亦持续增长，预计2030年将达约1.899亿人，2035年将达约2.217亿人，临床需求亟待满足。云顶新耀董事会主席吴以芳表示："我们非常高兴能与麦科奥特达成此次合作。在全球慢性肾脏病患者持续增加的背景下，继发性甲状旁腺功能亢进仍存在显著临床未满足需求。MT1013作为具备全球首创双重作用机制的临床后期创新资产，有望为SHPT患者提供全新的治疗选择。作为潜在同类最佳药物，MT1013将与公司现有的肾科产品组合形成高度协同，进一步夯实公司在肾科领域的布局。云顶新耀在持续深耕自身免疫相关肾脏疾病的基础上，正加速拓展至肾小球肾炎以及慢性肾脏病及其并发症等更广泛的治疗领域。此次合作是公司完善创新管线、拓展肾科治疗边界的重要战略举措，标志着肾科战略由聚焦单一疾病领域向系统化和平台化的发展阶段升级。未来，双方将协同推进MT1013的开发与商业化，为更广泛的肾病患者提供创新治疗选择。"麦科奥特创始人、董事长王冰博士表示："我们很高兴与云顶新耀达成此次战略合作。云顶新耀在肾病领域拥有深厚的市场积累和成熟的商业化体系，是推动MT1013惠及中国乃至全球患者的理想合作伙伴。MT1013是公司多肽技术平台的重要成果，代表着公司在慢病创新治疗领域深耕的重要里程碑达成，其独特的双靶点机制有望为SHPT治疗带来突破和更多获益。我们期待与云顶新耀紧密协作，加速该产品的临床开发和上市进程，共同满足广大未满足的临床需求，开启肾病领域治疗的全新篇章。"MT1013已完成关键II期临床研究，数据显示，MT1013在维持性血液透析伴SHPT患者中，展现出强效且持久的iPTH抑制能力，并在与依特卡肽头对头比较中实现了综合管理的优势——其iPTH、血钙、血磷三项同时达标率更高，降磷及降低心血管风险标志物FGF-23的优势更强，加之MT1013在长达52周的治疗中也为患者人群带来了显著的骨密度提升及骨代谢标志物改善，逐步验证了其独特的双重机制在SHPT患者中综合管理及改善骨骼健康方面的潜在临床获益。目前MT1013已进入以西那卡塞为阳性对照的确证性III期临床试验。该III期试验已在全国范围内启动超过100家研究中心，计划招募约424名患者，主要针对慢性肾脏病维持性血液透析伴 SHPT的患者群体。关于MT1013MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体（CaSR）及成骨生长肽（OGP）受体，开发主要用于治疗继发性甲状旁腺功能亢进症（SHPT），并计划拓展至包括慢性肾病性矿物质和骨代谢异常（CKD-MBD）伴骨质疏松及未接受透析的SHPT在内的额外适应症。MT1013已于2025年5月完成针对SHPT的II期临床研究（MT1013-II-C01），并已进入以西那卡塞为对照的III期临床研究。关于云顶新耀云顶新耀是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，致力于满足全球市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业拥有深厚的专长和丰富的经验。公司在浙江嘉善拥有具备商业化规模的全球生产基地，并严格按照国家药品监督管理局（NMPA）和欧洲药品管理局（EMA）的 GMP 要求及世界卫生组织（WHO）PQ 标准建设。公司聚焦自身免疫、眼科、急重症及CKM（心血管、肾脏及代谢）等疾病治疗领域，已打造集全渠道商业化体系与药品全生命周期商业化能力于一体的商业化平台，并以拥有全球权益的自研 mRNA 平台为基础，持续推进mRNA in vivo CAR-T 与 mRNA 肿瘤疫苗等现有管线，同时通过引进及生态孵化潜力平台，拓展研发能力，同时强化全球化布局，加快国际化发展进程。更多信息，请访问公司官网：www.everestmedicines.com。关于麦科奥特陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）于2007年1月在西安成立，现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业，致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业，聚焦于心脑血管、代谢类疾病相关领域的新药研发。公司是是双特异性多肽概念的提出者、实施者、验证者和开发者，是多肽类药物研发的优秀平台之一，具有筛选多靶点多肽药物的特殊机制，具备开发First-in-class和Best-in-class品种的平台型研发能力，现已储备多个新药品种，其中进入临床研发的有7个原研创新药管线，包括1个临床三期阶段，3个临床二期阶段，3个临床一期阶段。公司致力于创制新药、挽救生命，满足未被满足的临床需求，用科技创新为人类健康保驾护航。更多信息，请访问公司官网：www.micot.cn。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

JCN Newswire

Hitachi significantly expands exhibits at the “Hitachi Building Solutions Lab”, a research facility for collaborative creation with customers

February 4, 2026

- A branding area showcasing Hitachi’s journey from its founding to the vision it aims to achieve through Inspire 2027.(Top left)- A three-sided immersive theater presenting the future of buildings through powerful, engaging visual experiences.(Top right)- The entrance to the exhibition area where visitors can experience Hitachi’s comprehensive capabilities broughttogether under the One Hitachi. (Bottom left)- An interactive corner that visualizes and demonstrates commercial air conditioning control using augmented realitytechnology. (Bottom right)TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and Hitachi Building Systems Co., Ltd. (“Hitachi Building Systems”, part of Hitachi’s Connective Industries Sector (“CI Sector”)) will significantly expand the exhibits at “Hitachi Building Solutions Lab”, a customer co-creation research facility. The facility, located in Tokyo, will reopen in its new form on March 2, 2026. The exhibition is being expanded to accelerate digital innovation in the field of buildings, which are bases for people's activities, with a view toward the realization of a harmonized society where the environment, wellbeing and economic growth coexist in harmony as envisioned in the Inspire 2027, Hitachi Group's new management plan. To address social issues, including the decline in the working population and carbon neutrality, the new exhibition will use AI, digital twin, and augmented reality (AR) technologies to propose the latest solutions addressed by One Hitachi, including HMAX for Buildings: BuilMirai, a suite of next-generation solutions that combine domain knowledge and advanced AI.In the future, Hitachi and Hitachi Building Systems will advance collaborative creation with developers, design offices, construction companies, owners of buildings, building management companies and other customers, as well as with partners at the Hitachi Building Solutions Lab.Outline of the new exhibition1. Building management using physical AI realized using digital twin technologiesTo address the labor shortage in building management operations, the new exhibition will propose a future vision for building management in a demonstration that combines AI and digital twin solutions, based on the latest technologies being developed by Hitachi's Research & Development Group. Visitors will be able to experience a digital twin solution for the operation of a guide robot in a physical space after they view optimal solutions proposed by an AI agent based on the results of people flow analyses and provide instructions to the robot in a virtual space.2. Air conditioning and demand control solution to accelerate GX and ZEB*1The exhibition will propose solutions for decarbonizing and reducing energy expenses of buildings with a view toward the achievement of carbon neutrality in 2050. The Hitachi Building Solutions Lab will provide an experience-based exhibition that visualizes the exiida air conditioning IoT solution from Hitachi Global Life Solutions, Inc. (“Hitachi GLS”, part of Hitachi’s CI Sector) and controls an actual business-use air conditioning system using AR technologies.*1 GX: Green Transformation ZEB: Net Zero Energy Building3. Seeking seamless movement within buildings and wellbeingThe exhibition will propose experiences that facilitate seamless movement using integrated elevators and other building equipment with a view toward supporting people's diverse workstyles and increasing the safety and quality of life (QoL) of building users. It will enable visitors to experience the link between the connected features of Hitachi's standard elevator set to be released in April 2026 and mobile robots, connections with the Hybrid-PCS vehicle-to-everything (V2X) system*2 capable of supplying power to elevators and other building equipment by connecting to electric vehicles during a power outage, and the latest security system using an Apple Wallet authentication system*3 .*2 V2X: Vehicle to Everything (Technology enabling electric vehicles, residential houses, buildings and the power grid, etc. to supply power to each other by connecting vehicles to various devices and infrastructure.)*3 Contactless authentication system using smartphones. In this system, users' identification documents and driver's licenses are registered in the Apple Wallet application so that the user's identity and age can be verified in real time using Face ID, Touch ID or NFC.4. Strengthening comprehensive solution capabilities such as One Hitachi To address increasingly diverse and complicated social issues and mission-critical areas, the exhibition will showcase examples of the Hitachi Group's solutions in its broad range of business sectors centered on HMAX for Buildings and products in the CI Sector. They will include AI safety solutions*4 to facilitate increased work efficiency and improved safety for frontline engineers, Hitachi Industrial Equipment Systems Co., Ltd.'s generative AI agent for the provision of dialogue-based information on the operation and maintenance of industrial equipment, and Hitachi GLS' connected home appliances. This will strengthen Hitachi's comprehensive ability to propose solutions as One Hitachi.*4 News released on November 14, 2025: Hitachi Commences the On-Site Application of an AI-Based Safety Solution for Engineers in the Field — Dangerous Location Notification https://www.hitachi.com/New/cnews/month/2025/11/251114a.htmlOutline of the Hitachi Building Solutions Lab Address : 4-16-29 Nakagawa, Adachi-ku, TokyoDate of opening : April 2, 2023Closed on : Saturdays, Sundays, national holidays and Hitachi's non-business daysOperating hours : 10:00 a.m. to 5:00 p.m.Tour style : Fully attended tours by reservation only (In principle, tours are open only to developers, design offices, constructors, owners of buildings, management associations and other customers and partners.)Hitachi’s CI Sector focuses on “Integrated Industry Automation,” which aims to expand “HMAX Industry” into growth industries horizontally. HMAX Industry provides next-generation solutions for industry field that combine data from an abundant installed base of products (digitalized assets), domain knowledge, and advanced AI. As part of the CI Sector, Hitachi Building Systems aims to drive innovation for frontline engineers and contribute to improving people's wellbeing through the delivery of HMAX for Buildings: BuilMirai that embodies Lumada 3.0.An exhibit introducing AI safety solution for frontline engineers and Hitachi’s smart building services through digitalsignage, highlighting on-site transformation powered by AI.Trademark Notice: All trademarks and product names are the property of their respective owners.Hitachi Building Systems Websitehttps://www.hbs.co.jp/Hitachi Global Websitehttps://www.hitachi.com/businesses/elevator/About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

ACN Newswire

TANAKA PRECIOUS METAL TECHNOLOGIES在体外诊断试剂等的各种检测试剂盒的受托制造中确立全面解决方案体制

February 4, 2026

东京, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 专注于工业用贵金属展开业务的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（总公司：东京都中央区、执行总裁：田中浩一朗）宣布在以体外诊断试剂为代表的各种检测试剂盒的受托制造业务中，确立了可一站式应对整个工序的全面解决方案体制。TANAKA此前主要开展从检测试剂盒的开发制造到提取液的批量制造的相关业务，此次完善了提取液分装及包装的生产线，实现了在公司内部从开发到最终成品制造完成闭环的一条龙体制。由此不仅降低了外包和运输的相关成本，还缩短了生产周期，使我们能够以更短的期间提供更高质量的产品。此外，我们计划于2026年3月前追加引进最新型的自动装配生产线和提取液分装装置，以进一步扩大产能及缩短备货周期。TANAKA的全面解决方案体制通过强化一条龙生产体制实现灵活应对通过此次确立的全面解决方案体制，我们实现了从检测试剂盒开发制造，到提取液的批量制造及分装、包装等各工序的一站式受托服务。由此不仅能够对客户从开发阶段到量产的过程持续提供支持，还能应对仅药液分装等单一工序的委托。通过生产流程的公司内部闭环，来实现进一步强化稳定供应与质量管理。在广泛的疾病领域中的检测试剂盒的开发实绩与拓展示例我们提供针对流感、新型冠状病毒等呼吸道传染病，以及登革热病毒、寨卡病毒等范围广泛的传染病的体外诊断试剂。这些检测试剂盒可应对唾液、血液、尿液等多种检体，为在医疗领域实现快速精准的诊断提供支持。呼吸道传染病蚊媒传染病妇产科・流感病毒・腺病毒・RS病毒・人偏肺病毒・新型冠状病毒・A群β溶血链球菌（溶连菌）・登革热病毒・寨卡病毒・基孔肯雅热病毒・怀孕检测试剂TANAKA可检测疾病领域拓展示例技术基础与今后的展望TANAKA自2006年左右开始研发体外诊断试剂，不断培养以金（Au）胶体粒子为核心的相关技术。已拥有蛋白质固定化技术、非特异性吸附抑制技术、抗原抗体反应增强技术等，通过免疫层析法实现试剂更高性能化的多种技术。此外，还依托ISO 13485认证，有效利用这些技术，承接更高质量检测试剂盒的委托制造。今后仍将充分利用这一全面解决方案体制，在与合作伙伴企业协作的同时，致力于新型诊断试剂的开发工作，并为解决社会课题和推动医疗领域的发展做出贡献。关于TANAKATANAKA自1885 年（明治18年）创业以来，营业范围以贵金属为中心，并以此展开广泛活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售，以及提供作为宝石饰品及资产的贵金属商品。并且，作为贵金属相关的专家集团，日本国内外的各集团公司进行制造、销售以及技术一体化，携手合作提供产品及服务。2024年度（截至2024年12月)集团总营业额为8,469亿日元，拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: https://www.acnnewswire.com/docs/files/20260205_CH.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE.NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Bitdeer宣布将于2026年2月12日召开2026年第四季度收益电话会议

February 4, 2026

(SeaPRwire) - 新加坡，2026年2月4日 -- Bitdeer Technologies Group (NASDAQ: BTDR)（“Bitdeer”或“公司”），一家全球领先的比特币挖矿和人工智能基础设施技术公司，今日宣布其第四季度2025财报电话会议和网络直播定于美国东部时间2026年2月12日（星期四）上午8:00举行。届时，Bitdeer管理层将讨论截至2025年12月31日的季度未经审计的财务和运营业绩，随后进行问答环节。 Bitdeer将于2026年2月12日上午7:00左右（美国东部时间）在电话会议前发布第四季度业绩。收益报告副本将在公司投资者关系网站上提供。电话会议信息：日期：2026年2月12日时间：美国东部时间上午8:00 / 新加坡时间晚上9:00 参会者电话链接：直播网络会议：参会者电话注册：希望通过电话参加电话会议的参会者应使用上方提供的参会者电话注册链接进行注册。完成注册后，参会者将收到一封包含接入电话所需详细信息的电子邮件，包括拨入号码、密码和PIN码。为确保准时开始，公司鼓励所有来电者提前约5分钟接入。电话会议的直播和存档网络会议将在Bitdeer网站的投资者部分提供。关于Bitdeer Technologies Group Bitdeer是一家全球领先的比特币挖矿和人工智能基础设施技术公司。Bitdeer致力于为客户提供全面的比特币挖矿解决方案。公司负责处理计算中的复杂流程，如设备采购、运输物流、数据中心设计和建设、设备管理以及日常运营。公司还为对人工智能有高需求需求的客户提供先进的云能力。Bitdeer总部位于新加坡，已在美国、挪威和不丹部署了数据中心。欲了解更多信息，请访问或在X @ 和LinkedIn @ 上关注Bitdeer。投资者和其他人士应注意，Bitdeer可能会通过其网站和/或其在社交媒体平台（包括X，前身为Twitter，Facebook和LinkedIn）上的账户发布重大信息。因此，Bitdeer鼓励投资者和其他人士审阅其在网站上列出的社交媒体和其他沟通渠道上发布的信息。投资者和媒体垂询，请联系：投资者关系ICRJohn Ragozzino 公共关系BlocksBridge ConsultingNishant Sharma本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Orangekloud Technology Inc. 宣布纳斯达克退市决定函

February 4, 2026

(SeaPRwire) - 新加坡，2026年2月4日——总部位于新加坡的科技公司Orangekloud Technology Inc.（纳斯达克股票代码：ORKT，以下简称“Orangekloud”或“公司”）提供eMOBIQ®️无代码平台用于开发移动应用，该公司今日宣布，其于2026年1月29日收到纳斯达克上市资格部门员工（以下简称“员工”）发出的员工退市决定函。该函件指出，由于公司证券在过去30个连续营业日的收盘价均低于每股1美元，不符合上市规则5550(a)(2)的要求，且公司在过去一年内进行了反向股票分割，因此无资格获得上市规则5810(c)(3)(A)项下通常给予的180个日历日合规证明期，员工决定启动公司普通股从纳斯达克资本市场（以下简称“纳斯达克”）退市的程序。公司拟根据纳斯达克上市规则5815，向纳斯达克听证委员会（以下简称“委员会”）提交口头听证申请，对员工决定提出上诉。根据规则5815(a)(1)(B)，申请提交后，将暂停公司证券的交易停牌或退市程序，直至听证结束及委员会作出决定。在此期间，公司证券将继续在纳斯达克资本市场以“ORKT”为代码正常交易。根据上市规则5815(a)(5)，公司将向听证委员会提交书面合规计划，并请求委员会根据规则5815(c)(1)(A)的规定，给予上市标准的有限期豁免。然而，无法保证委员会会批准公司恢复合规的计划及/或授予所请求的豁免，也无法保证该计划若实施将取得成功。公司发布本公告是为了履行上市规则5810(b)项下的义务，即在收到相关缺陷和员工决定后的四个工作日内进行公开披露。关于Orangekloud Technology Inc. Orangekloud Technology Inc.（纳斯达克股票代码：ORKT）是一家总部位于新加坡的科技公司，提供eMOBIQ®无代码平台，专为中小企业（SMEs）和企业开发移动应用。公司拥有一系列eMOBIQ®移动应用，旨在实现仓储、销售订单、配送、制造及其他关键领域运营的数字化和流程优化。专注的行业领域包括食品服务与制造、精密工程、建筑等。前瞻性陈述本新闻稿中包含的有关未来预期、计划和前景的某些陈述，以及任何非历史事实的陈述，可能构成《1995年私人证券诉讼改革法案》所定义的“前瞻性陈述”。这些陈述包括但不限于与预期交易开始和结束日期相关的陈述。“预期”“相信”“继续”“可能”“估计”“期望”“打算”“可能”“计划”“潜在”“预测”“项目”“应该”“目标”“将”“会”等词语旨在识别前瞻性陈述，但并非所有前瞻性陈述都包含这些识别词。由于各种重要因素，实际结果可能与前瞻性陈述所指示的结果存在重大差异，包括：与市场状况及公开发行能否按预期条款完成或能否完成相关的不确定性，以及提交给美国证券交易委员会（SEC）的初步招股说明书中“风险因素”部分讨论的其他因素。因此，投资者应谨慎对待本新闻稿中的前瞻性陈述，不应过度依赖。本新闻稿中的任何前瞻性陈述仅代表截至本公告发布之日的观点，OrangeKloud Technology Inc.明确不承担任何更新前瞻性陈述的义务，除非法律要求，无论更新原因是新信息、未来事件或其他情况。联系方式 Orangekloud Technology Inc. 投资者关系联系人：Steven Chu，首席运营官兼投资者关系官新加坡本德米尔路70号 Luzerne 04-04室新加坡 339940电话：(+65) 6317 2050电子邮箱：投资者关系咨询：Skyline Corporate Communications Group, LLCScott Powell，总裁美洲大道1177号5楼纽约州纽约市 10036办公室电话：(646) 893-5835电子邮箱：本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

2026年超级碗：关于本届赛事你需要知道的一切

February 4, 2026

(SeaPRwire) - 西雅图海鹰队和新英格兰爱国者队将于周日在NFL年度的______中对决。超级碗LX是______的重赛，当时西雅图海鹰队时任四分卫拉塞尔·威尔逊（Russell Wilson）在一码线上被最后时刻抄截，导致______。如今，爱国者队和海鹰队都有了新的首发四分卫——前者由23岁的德雷克·梅伊（Drake Maye）领衔，后者由28岁的萨姆·达诺德（Sam Darnold）担任。据______报道，这是超级碗历史上首次出现两支球队的首发四分卫和主教练（爱国者队的迈克·弗拉贝尔（Mike Vrabel）和海鹰队的迈克·麦克唐纳（Mike Macdonald））均处于在该队的第一个或第二个赛季。无论你是为了观看精彩的橄榄球比赛、中场表演还是______而看比赛，以下是关于2026年超级碗你需要了解的一切。 2026年超级碗何时何地举行？超级碗LX将于2026年2月8日周日美国东部时间晚上6:30/当地时间下午3:30举行。比赛将在加利福尼亚州圣克拉拉的Levi’s Stadium举行，该体育场是旧金山49人队的主场，位于旧金山湾区。如何观看2026年超级碗？超级碗将在全国范围内通过NBC、Telemundo和Universo播出。你也可以通过流媒体服务观看比赛，包括Peacock、NFL+、Hulu + Live TV、DIRECTV和YouTube TV。 2026年超级碗中场秀由谁表演？六次格莱美奖得主Bad Bunny将在中场秀表演，就在他在第68届格莱美奖上斩获三项大奖（包括年度专辑奖______）一周后。这位波多黎各艺术家可能会表演他六张专辑中的歌曲，这些专辑深入探讨波多黎各和拉丁传统。Bad Bunny中场秀的预告片承诺，演出期间“全世界都会起舞”，而关于他可能邀请谁同台的预测从Cardi B到Rosalía再到Jennifer Lopez不等。2020年，Lopez邀请Bad Bunny加入她和夏奇拉（Shakira）的超级碗中场秀表演，他在其中说唱了《I Like It》中的自己的段落以及热门歌曲《Callaita》的一部分。在今年格莱美奖的获奖感言中，Bad Bunny抨击了近期的移民打击行动以及美国移民和海关执法局（ICE）针对移民和抗议者的行为。 “在感谢上帝之前，我要说：ICE滚出去！”他说。“我们不是野蛮人，不是动物，不是外星人。我们是人，我们是美国人。” 这番言论让公众好奇，他的中场秀是否会包含类似尖锐的政治信息。其他音乐人也将登台，包括将演唱国歌的Charlie Puth，以及将在开幕式表演的Green Day。每支球队参加过多少次超级碗？美国橄榄球联合会（AFC）的爱国者队将第12次晋级超级碗，创下纪录——这是传奇四分卫汤姆·布雷迪（Tom Brady）2020年离开球队后的首次超级碗之旅。布雷迪带领球队参加了10次超级碗，赢得了6次梦寐以求的冠军。如果爱国者队周日获胜，他们将以7次冠军打破NFL超级碗冠军次数纪录，超过匹兹堡钢人队。目前两队均以6次冠军打平。这将是西雅图海鹰队第四次参加超级碗，不过他们只在2014年击败丹佛野马队赢得过一次冠军。门票多少钱？ Levi’s Stadium（约有68500个座位）的官方观赛门票已售罄。这些门票价格从950美元到8000多美元不等。但在StubHub和SeatGeek等转售平台上仍有门票出售，价格从4000美元到60000美元不等。根据Vivid Seats的数据，零售门票的中位入门价目前为7497美元。今年超级碗期间的广告费用是多少？对于广告商来说，超级碗不仅仅提供体育赛事；它还提供了一个将产品展示给数百万观众的机会，这就是为什么他们常常全力以赴脱颖而出。今年，30秒广告时段的费用据报道高达1000万美元，平均约为800万美元。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

他在1月6日保卫了国会大厦。现在他正竞选国会众议员，并将ICE比作暴徒

February 4, 2026

(SeaPRwire) - 本文是《华盛顿简讯》（TIME的政治新闻通讯）的一部分。订阅即可将此类报道发送至你的收件箱。当哈里·邓恩（Harry Dunn）观看明尼阿波利斯联邦移民官员的视频画面时，他不禁想起2021年1月6日在美国国会大厦发生的事件。 “他们与其说是在服务，不如说是在恐吓民众，” 曾担任国会警察的邓恩在谈到这些移民官员时对我说道。“而执法本应是关于服务的。但我们现在看到的并非如此。” 对邓恩来说， dismantle 唐纳德·特朗普的移民体系将是他周三上午启动的马里兰州空缺席位美国众议院竞选的核心纲领。这一承诺与他在1月6日的经历紧密相关，正是这段经历让他在三年内第二次竞选国会席位。 “我希望成为这样的人：站在中间，为这个社区和全国受苦的人们挺身而出，” 邓恩在竞选启动前一天接受《时代》杂志采访时表示。“从1月7日起，我就一直在做这件事。” 作为特朗普鼓励支持者前往国会山抗议国会认证乔·拜登2020年胜利后受伤的140名国会警察之一，邓恩已成为特朗普当天角色的直言不讳的批评者，也意外地成为那些在保护议员时面临政治暴力威胁的警察的。当天，暴徒向他投掷种族主义污言秽语、烟雾弹和拳头。到事件结束时，他自己的拳头也因试图击退他所称的“恐怖分子”人群而沾满鲜血。 “我们现在不是在正常时期，” 邓恩告诉我。“我们正处于911紧急状态，现在需要第一响应者。” 邓恩向他游说成立的、类似9·11委员会的调查袭击事件小组作证。他出席了所有听证会。他还指证了一些被控参与袭击的人。他被授予国会金质奖章和总统公民奖章，并出版了一本关于这段经历的回忆录。邓恩于2013年从警队辞职。两年前，他寻求代表以安纳波利斯为基地的马里兰州第三选区的民主党提名。该党的许多全国性人物。当他获得第二名时，他迅速 endorsement 对手、现任首届众议员萨拉·埃尔弗雷思（Sarah Elfreth），并开始努力帮助乔·拜登（Joe Biden），后来又帮助卡玛拉·哈里斯（Kamala Harris）阻止特朗普。 “我在上次竞选时谈到的很多事情，现在都发生了，” 邓恩说。“当时每个人都说，‘哦，你们反应过度了。这家伙不会成为独裁者。有制衡机制。’” “我们现在的国会不仅对他的所作所为视而不见，还在纵容他，” 邓恩说。邓恩表示，直到明尼阿波利斯的亚历克斯·普雷蒂（Alex Pretti）被协助ICE的海关和边境保护局（Customs and Border Control）官员杀害，他才最终决定再次参选——尽管自他离开警队以来，他在政治圈一直相当活跃。鉴于他的背景和竞选启动的重点，我向邓恩提出了一个简单的问题：执法部门现在还值得我们信任吗？他的回答很有说服力——对寻求温和回应的民主党同僚来说，这可能是一个可信的选择。 “有一些执法人员每天都在尊重地履行职责，为社区服务。然而，我们看到一个、两个坏苹果绝对会毁掉整筐苹果，” 他说道，随后批评了作为警察主要政治代言人的工会。“警察兄弟会（Fraternal Order of Police）在唐纳德·特朗普的最后三次选举中都支持了他，包括1月6日之后的那次。” “那ICE应该怎么办？” 我问道，考虑到普雷蒂和蕾妮·古德（Renee Good）在明尼阿波利斯的死亡，以及特朗普政府的移民官员。 “这不是训练的问题。这是心态的问题。是思维方式的问题。我不知道你如何通过训练来改变心态，” 他说。“他们逮捕的是女佣、酒店员工、农场工人、厨师和建筑工人。他们并没有像唐纳德·特朗普所说的那样，针对强奸犯和杀人犯。”（他很快补充道：“当然，强奸犯和杀人犯绝对应该被绳之以法。”）马里兰州初选的报名截止日期要到本月晚些时候才到，从现在到6月的初选还有很长时间。邓恩曾是华盛顿和捐赠者中的热门人选，但两年前这并没有转化为胜利。不过这一次，移民官员在平民社区行动的画面在选民心中记忆犹新。这也是邓恩的宣布视频将1月6日的事件与当前事件直接联系起来的部分原因。“我在ICE特工身上看到了与1月6日暴动者相同的攻击性：不受约束的武力、美国公民被谋杀，以及用来掩盖真相的谎言，” 邓恩在发布视频中说。“告诉唐纳德·特朗普，我要回到国会大厦了，这次我有投票权、监督权和传票权……我准备完成我开始的工作。我将再次捍卫这个国家。” 邓恩表示，如果不是觉得有必要，他可能不会把竞选重心放在1月6日事件上——因为特朗普回到了白宫，赦免了暴动者，并继续歪曲那一天的事实。 “很多人说，‘这家伙只谈论1月6日的事，’” 邓恩告诉我。“我最希望的就是不用再谈论1月6日，但我不会允许本届政府说谎、编造虚假信息，把那天描绘成充满爱与和平的一天。” 了解华盛顿的重要事务。 .本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

ACN Newswire

爱克发医疗荣膺2026年KLAS(R)美国三大企业影像领域最佳供应商

February 4, 2026

莫尔塞尔，比利时, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 阿格法医疗今日宣布，其在美国三大企业影像领域荣获2026年度KLAS®最佳企业称号，其中两项奖项实现连续两年蝉联，彰显了公司在提供以临床医师为核心的影像解决方案方面持续领先的地位，该方案已赢得全球医疗机构的信赖。此次获奖正值KLAS研究公司成立三十周年之际，该机构三十年来始终通过独立、数据驱动的洞察力，为医疗服务提供者发声。阿格法医疗荣获“KLAS最佳”殊荣，充分体现其企业影像平台获得客户高度认可。该平台旨在赋能临床医生保持工作流畅性，简化影像工作流程复杂性，并通过互联高效的影像数据访问能力，助力临床决策信心提升。KLAS®最佳企业影像解决方案（美国）放射学企业影像：在PACS（小型——低于30万份研究）细分领域以93.2%的评分位列榜首。XERO® 影像浏览器：连续三年蝉联通用影像浏览器领域榜首，评分达92.1%企业级影像VNA系统：连续两年稳居供应商中立档案系统（VNA）领域首位，评分达89.8%“在三大企业影像领域获得认可——包括多次蝉联冠军——有力印证了我们以临床医生为核心的战略，”爱克发医疗总裁娜塔莉·麦考利表示，"医疗机构信赖我们打造的影像环境，既能切实支持临床医生的日常工作，又能让IT和临床领导者充满信心地高效运作并具备长远视野。这项荣誉彰显了我们合作伙伴关系的强大力量，以及我们始终如一地致力于通过互联智能影像赋能医疗团队。"KLAS Research首席执行官亚当·盖尔对此评价道：“最佳KLAS奖项得主在过去一年赢得了客户的信任。这份认可将为未来数月医疗技术与服务领域的卓越合作树立标杆。”KLAS Research全球影像业务副总裁莫妮克·拉斯班德补充道：“阿格法医疗在多个企业影像细分领域的卓越表现，充分体现了客户的一致认可。医疗机构深知这类解决方案的价值——既能助力影像团队提升当下工作效率，又为未来的增长与创新铺就清晰路径。”“KLAS最佳”奖项基于医疗机构的直接反馈评选，旨在表彰那些通过合作伙伴关系、卓越表现及对客户需求的敏捷响应，持续展现卓越品质的供应商。阿格法医疗将在2026年HIMSS大会期间与客户及合作伙伴共同庆祝此次KLAS最佳奖项，以此践行其持续推进大规模互联、智能且以人为本的影像解决方案的承诺。KLAS参考资料最佳KLAS奖项概述：《2026最佳KLAS奖项：软件与服务报告》企业影像细分领域报告：《2026最佳KLAS奖项：软件与服务报告》关于爱格华医疗在爱格华医疗，我们深知临床效率与优质患者护理之间的关键平衡始于临床医生的体验。我们认识到临床医生全情投入病例、倾注全部精力做出自信而明智的诊断至关重要。正因如此，我们设计了企业影像平台，旨在消除阻碍这一目标的障碍。当干扰消弭，技术便成为思维的自然延伸，每位临床医生都能获得发挥专业精髓所需的一切。这便是“顺势而为”的真谛。这一理念贯穿我们所有行动——以使命宣言、愿景蓝图及客户交付原则为指引，致力于赋能临床工作者并提升其体验。爱克发医疗是爱克发集团旗下业务部门。如需了解更多关于爱克发医疗的信息，请访问 www.agfahealthcare.com 并关注我们的领英主页。AGFA及Agfa菱形标识均为比利时Agfa-Gevaert N.V.或其关联公司的注册商标。XERO为比利时Agfa HealthCare N.V.或其关联公司的注册商标。本文所含信息仅供参考，本出版物所述产品及服务的特性可随时变更，恕不另行通知。部分产品及服务可能无法在您所在地区提供。具体供应信息请咨询当地销售代表。AGFA HealthCare竭力确保信息准确性，但对任何印刷错误概不负责。关于KLAS研究KLAS研究是一家领先的医疗保健IT数据与洞察公司，致力于通过放大医疗服务提供者的声音来改善全球医疗服务。KLAS将于2026年迎来成立30周年，通过基于直接客户反馈的独立研究评估供应商表现。Best in KLAS®是KLAS研究的注册商标。媒体联络人：杰西卡·巴尔德里，爱克发医疗全球市场与传播经理电话：+44 1206 413052邮箱：jessica.baldry@agfa.com 来源：爱克发医疗 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

1 …22 23 24 25 26 … 28